APP
PRME icon

Alpha Paradigm Partners’s Prime Medicine PRME Stock Holding History

Alpha Paradigm Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$72K Buy
+3,895
New +$70.4K 0.03% 402

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alpha Paradigm Partners's PRME Position: Q4 2022 in Review

Alpha Paradigm Partners opened a new position in Prime Medicine (PRME) in Q4 2022: 3,895 shares worth $72K. The stake represents 0.03% of the portfolio and ranks #402 among its holdings.

66 funds tracked by Wall St. Rank hold PRME as of Q4 2022.

  • Alpha Paradigm Partners held 3,895 shares of Prime Medicine worth $72K as of Q4 2022.
  • Prime Medicine was a new Alpha Paradigm Partners position in Q4 2022.
  • Prime Medicine made up 0.03% of Alpha Paradigm Partners's portfolio in Q4 2022, its #402 holding.
  • 66 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.